Status
The Tribunal made an order on 3 August 2021 granting the Cinven Parties an extension of time to file a notice of appeal against, respectively, the CMA's Hydrocortisone Decision and the CMA's Liothyronine Decision due to exceptional circumstances.
By Order of the Chairman dated 5 October 2021, the time for the CMA to file a single Defence in the Hydrocortisone appeals was extended to 1 December 2021.
Summary of appeal published on 27 October 2021.
A case management conference took place on 8 December 2021, at which the Tribunal made case management directions and ordered that all appeals of the CMA's Hydrocortisone Decision will be case managed together (the "Hydrocortisone Proceedings").
A second case management conference took place remotely on 21 January 2022, following which the Tribunal made directions for the Hydrocortisone Proceedings to be progressed and case managed through the use of Ambulatory Drafts.
The third case management conference in this matter took place on 25 July 2022.
The Hydrocortisone Proceedings were heard from 22 November to 23 December 2022, with additional hearing days on 25 January 2023 and 3 February 2023.
Judgment was handed down in relation to the Abuse of Dominance Infringements (as defined in that judgment) on 18 September 2023 ([2023] CAT 56). Judgment was handed down in a closed judgment in relation to the Cartel Infringements on 29 September 2023 ([2023] CAT 57).
A closed hearing to deal with consequential matters in relation to [2023] CAT 57 took place on 26 and 27 October 2023 - see the Order of the President of 29 September 2023. Judgment in relation to due process was handed down on 8 March 2024 ([2024] CAT 17). An Order of the President was made on the same date regarding matters consequential to that Judgment, and regarding open publication of [2023] CAT 57.
Judgment was handed down on 29 April 2024 in relation to the outstanding ground of appeal regarding penalties ([2024] CAT 29). No consequentials hearing will be listed.
